2Strands Biosciences was selected as one of 20 high-potential companies for MedTech Innovator’s 2025 Asia Pacific Accelerator, following a competitive selection process involving more than 550 applicants.
MedTech Innovator is the world’s largest accelerator for medical device, diagnostic and digital health companies. Through the programme, 2Strands gained access to mentorship, industry partners, investors and a global network supporting the development of transformative healthcare technologies.
Our founder, Debleena Ray, represented 2Strands at the invitation-only Innovator Summit, held on 25–26 June 2025 in Mountain View, California, where she presented the company’s ultrasensitive ctDNA detection technology for minimal residual disease (MRD) monitoring.
Read more about the 2025 cohort on MedTech Innovator’s website: https://medtechinnovator.org/twenty-high-potential-startups-selected-for-medtech-innovators-2025-asia-pacific-accelerator/